Total Funding
21
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
249032
Kiadis Pharma is a biopharmaceutical company offering novel treatment options for terminally ill cancer patients.
Robert Ian James: DirectorPast Role: Oxford Immunotec, Non-Executive Director- Robert Friesen: Chief Scientific Officer
About the Company
Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is
headquartered in Amsterdam, The Netherlands.
